First-in-class p53 reactivator shows activity in advanced solid tumours
Initial results of a phase II trial with rezatapopt suggest real promise in an area that has eluded druggable targeting
Going beyond protocol is key for young people with cancer
For adolescents and young adults with cancer, individualised care that addresses their unique medical and psychosocial needs is essential to improving outcomes and quality of life
A new claudin 18.2-targeting approach appears promising in gastric cancers
A triple combination investigated in a phase I trial adds to the growing therapeutic options directed at this emerging target
Bridging the interpretation gap in cancer genomics – the next frontier for ai in oncology
Can artificial intelligence finally unlock the full potential of cancer genomics? Discover how new digital tools are closing the gap between data and clinical action in oncology.
AI-powered three-dimensional tumour pathology
Computational models can overcome current limitations of 3D analysis of tumour samples
AI tool outperforms manual PD-L1 scoring in a study
Integrating artificial intelligence into pathology routine workflows could optimise patient selection for immunotherapy
Is there still a role for anti-TIGIT therapy in hepatocellular carcinoma?
While the IMbrave152/SKYSCRAPER-14 trial showed no added benefit with tiragolumab, other studies are ongoing to explore the potential of additional immune checkpoint inhibition in combination with standard therapy
The first ESMO guidance for AI-based biomarkers
In a newly released framework paper, ESMO defines criteria for assessing and implementing AI-based biomarkers in oncology
Ma: “We all need more than one mentor”
For Prof. Brigette Ma, dealing with diversity and finding opportunities in criticisms are essential to grow as oncology professionals
Artificial intelligence as a reliable research partner
Extensive research is focusing on the development of tools that may enhance drug development and personalised oncology in the near future